These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

948 related items for PubMed ID: 16828054

  • 1. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
    Théoleyre S, Kwan Tat S, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, Fortun Y, Padrines M, Rédini F, Heymann D.
    Biochem Biophys Res Commun; 2006 Aug 25; 347(2):460-7. PubMed ID: 16828054
    [Abstract] [Full Text] [Related]

  • 2. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines.
    Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H.
    Biochem Biophys Res Commun; 2000 Sep 07; 275(3):768-75. PubMed ID: 10973797
    [Abstract] [Full Text] [Related]

  • 3. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T, Utsuyama M, Hirokawa K.
    J Bone Miner Res; 2001 Aug 07; 16(8):1416-25. PubMed ID: 11499864
    [Abstract] [Full Text] [Related]

  • 4. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland.
    Hofbauer LC, Kluger S, Kühne CA, Dunstan CR, Burchert A, Schoppet M, Zielke A, Heufelder AE.
    J Cell Biochem; 2002 Aug 07; 86(4):642-50. PubMed ID: 12210731
    [Abstract] [Full Text] [Related]

  • 5. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK, Chen YL, Chang HC, Li CL, Kuo MY.
    J Periodontal Res; 2006 Aug 07; 41(4):354-60. PubMed ID: 16827732
    [Abstract] [Full Text] [Related]

  • 6. Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL.
    Middleton-Hardie C, Zhu Q, Cundy H, Lin JM, Callon K, Tong PC, Xu J, Grey A, Cornish J, Naot D.
    J Bone Miner Res; 2006 Mar 07; 21(3):438-45. PubMed ID: 16491292
    [Abstract] [Full Text] [Related]

  • 7. RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family.
    Mori T, Oguro A, Ohtsu T, Nakamura Y.
    Nucleic Acids Res; 2004 Mar 07; 32(20):6120-8. PubMed ID: 15562003
    [Abstract] [Full Text] [Related]

  • 8. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
    Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D.
    Cytokine Growth Factor Rev; 2004 Dec 07; 15(6):457-75. PubMed ID: 15561602
    [Abstract] [Full Text] [Related]

  • 9. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
    Koh JM, Lee YS, Byun CH, Chang EJ, Kim H, Kim YH, Kim HH, Kim GS.
    J Endocrinol; 2005 Jun 07; 185(3):401-13. PubMed ID: 15930166
    [Abstract] [Full Text] [Related]

  • 10. Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.
    Regmi A, Fuson T, Yang X, Kays J, Moxham C, Zartler E, Chandrashekhar S, Galvin RJ.
    Bone; 2005 Feb 07; 36(2):284-91. PubMed ID: 15780954
    [Abstract] [Full Text] [Related]

  • 11. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
    Mandelin J, Li TF, Hukkanen M, Liljeström M, Salo J, Santavirta S, Konttinen YT.
    J Rheumatol; 2005 Apr 07; 32(4):713-20. PubMed ID: 15801030
    [Abstract] [Full Text] [Related]

  • 12. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.
    Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC.
    Calcif Tissue Int; 2004 Jan 07; 74(1):103-6. PubMed ID: 14523602
    [Abstract] [Full Text] [Related]

  • 13. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
    Fábrega E, Orive A, García-Unzueta M, Amado JA, Casafont F, Pons-Romero F.
    Clin Transplant; 2006 Jan 07; 20(3):383-8. PubMed ID: 16824158
    [Abstract] [Full Text] [Related]

  • 14. [New paradigms in the regulation of bone metabolism].
    Rosa-Rañal M, de la Cruz DA, Lorena-Rubio Y, Larrea F.
    Rev Invest Clin; 2001 Jan 07; 53(4):362-9. PubMed ID: 11599485
    [Abstract] [Full Text] [Related]

  • 15. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
    Lossdörfer S, Schwartz Z, Wang L, Lohmann CH, Turner JD, Wieland M, Cochran DL, Boyan BD.
    J Biomed Mater Res A; 2004 Sep 01; 70(3):361-9. PubMed ID: 15293309
    [Abstract] [Full Text] [Related]

  • 16. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
    Cross SS, Harrison RF, Balasubramanian SP, Lippitt JM, Evans CA, Reed MW, Holen I.
    J Clin Pathol; 2006 Jul 01; 59(7):716-20. PubMed ID: 16489180
    [Abstract] [Full Text] [Related]

  • 17. TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis.
    Abu-Amer Y, Abbas S, Hirayama T.
    J Cell Biochem; 2004 Nov 15; 93(5):980-9. PubMed ID: 15389885
    [Abstract] [Full Text] [Related]

  • 18. OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation.
    Tat SK, Padrines M, Theoleyre S, Couillaud-Battaglia S, Heymann D, Redini F, Fortun Y.
    Bone; 2006 Oct 15; 39(4):706-15. PubMed ID: 16750945
    [Abstract] [Full Text] [Related]

  • 19. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization.
    Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Müller F, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damås JK, Frøland SS, Hansson GK, Halvorsen B, Aukrust P.
    Arterioscler Thromb Vasc Biol; 2006 Apr 15; 26(4):857-63. PubMed ID: 16424351
    [Abstract] [Full Text] [Related]

  • 20. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
    Fábrega E, Orive A, García-Suarez C, García-Unzueta M, Antonio Amado J, Pons-Romero F.
    Liver Int; 2005 Apr 15; 25(2):305-10. PubMed ID: 15780054
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.